Leukemia
CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75Yyears of Age with Untreated High Risk (secondary) AML
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01696084
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Investigator: Oliver Press, M.D.; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia; Status: Closed; Study ID: NCT01290549
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR
Investigator: Vivian Oehler, MD; Conditions: Chronic Myeloid Leukemia (CML); Status: Recruiting; Study ID: NCT00686218
Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Investigator: Blythe Thomson, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Recruiting; Study ID: NCT00408005
A Phase 1, Dose Escalation Study of Plerixafor in combination with Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia
Investigator: Pamela Becker, MD, PhD; Conditions: De Novo Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT00990054
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome
Investigator: Pamela Becker, MD, PhD; Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS); Status: Closed; Study ID: NCT01101880
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia (CLL); Status: Recruiting; Study ID: NCT01188681
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT01141725
Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients in First Complete Remission
Investigator: Elihu Estey, MD; Conditions: WT1-positive Acute Myeloid Leukemia; Status: Ongoing--Not Recruiting; Study ID: NCT00725283
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Investigator: John M. Pagel, MD; Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT01578707
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Investigator: Bart Scott, MD; Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML); Status: Closed; Study ID: NCT00528983
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01539291
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Pending; Study ID: NCT01539512
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant
Investigator: Brenda Sandmaier, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01468467
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT01398462
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01569295
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT00476047
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Investigator: John Pagel, MD, PhD; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00918723
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Closed; Study ID: NCT00953758
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age
Investigator: John Pagel, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT00839982
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Investigator: Roland B. Walter, MD; Conditions: Relapsed or Refractory Leukemia; Status: Closed; Study ID: NCT00920140
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01120457
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01165112
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML
Investigator: Merav Bar, MD; Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia; Status: Recruiting; Study ID: NCT01640301
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT01701323
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01567059
A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01632852
A Phase 2, Randomized, Open-label study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01565668
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Investigator: Vivian Oehler, MD; Conditions: Chronic Myeloid Leukemia; Status: Recruiting; Study ID: NCT01650805
A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Investigator: Andrei Shustov, MD; Conditions: Acute Lymphoid Leukemia; Status: Recruiting; Study ID: NCT01439347
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01756677
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01729845
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01349049
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01465386
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Investigator: John M. Pagel, MD; Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT00988715
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations
Investigator: Elihu Estey, MD; Conditions: Acute Myeloid Leukemia; Status: Closed; Study ID: NCT00989261
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: Ajay K. Gopal, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Closed; Study ID: NCT01300247
COG - Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group Wide Study
Investigator: Blythe Thomson, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Closed; Study ID: NCT00103285
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT01342887
A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphoid Leukemia (CLL); Status: Closed; Study ID: NCT00845104
Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT00795002
Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT01031368
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML
Investigator: Derek L. Stirewalt, MD; Conditions: Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01607645
Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-the-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies
Investigator: Colleen Delaney, MD; Conditions: Leukemia; Status: Pending; Study ID: NCT01690520
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT01807091
Join Us On